Latest BVXV reports update at 2023-12-23: 2021 ∙ 2020 ∙ 2019

BiondVax Pharmaceuticals Ltd. BVXV

$ 1.36 0.74%

BiondVax Pharmaceuticals Ltd. Balance Sheet 2011-2024 | BVXV

Annual Balance Sheet BiondVax Pharmaceuticals Ltd.

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	52 M	18.5 M	-	-15.7 M	-33.5 M	-9.61 M	-17.9 M	-11 M	-
Long Term Debt	-	-	124 M	94.4 M	-	-	-	-	-	-	-
Long Term Debt Current	773 K	654 K	694 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	7.32 M	162 M	115 M	18.6 M	3.12 M	6.06 M	62 K	55 K	48 K	-
Total Current Liabilities	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	71.5 M	181 M	137 M	25.4 M	4.49 M	7.76 M	1.88 M	1.84 M	1.02 M	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-325 M	-320 M	-211 M	-123 M	-88.9 M	-79.7 M	-69.5 M	-61.7 M	-53.7 M	-
Total Assets	99.6 M	56.9 M	116 M	106 M	81.7 M	30.1 M	41.3 M	18.5 M	25.8 M	23.2 M	-
Cash and Cash Equivalents	54 M	9.42 M	72.5 M	75.9 M	71.4 M	15.7 M	33.5 M	-	-	-	-
Book Value	99.6 M	-14.6 M	-65.1 M	-31.2 M	56.3 M	25.6 M	33.5 M	16.6 M	24 M	22.2 M	-
Total Shareholders Equity	-	-14.6 M	-65.1 M	-31.2 M	56.3 M	25.6 M	33.5 M	-	-	-	-

All numbers in ILS currency

Quarterly Balance Sheet BiondVax Pharmaceuticals Ltd.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	69.1 M	6.57 M	-	-	7.32 M	65.6 M	141 M	-	162 M	137 M	138 M	-	115 M	-	-	-	18.6 M	-	-	-	3.12 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-365 M	-354 M	-	-	-325 M	-311 M	-366 M	-	-320 M	-277 M	-258 M	-	-211 M	-	-	-	-123 M	-	-	-	-88.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	-	99.6 M	81 M	-	-	56.9 M	74.9 M	85.7 M	-	116 M	119 M	75.8 M	-	106 M	-	-	-	81.7 M	-	-	-	30.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	-	54 M	34.7 M	42.5 M	-	9.42 M	24.8 M	38.8 M	42.5 M	72.5 M	75.2 M	33.9 M	57.4 M	75.9 M	-	-	-	71.4 M	-	-	-	15.7 M	-	-	-	33.5 M	-	-	-	9.61 M	192 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	-	99.6 M	81 M	-	-	56.9 M	74.9 M	85.7 M	-	116 M	119 M	75.8 M	-	106 M	-	-	-	81.7 M	-	-	-	30.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	-	23.3 M	4.19 M	11.4 M	-	-14.6 M	-1.84 M	-61.9 M	-61.3 M	-65.1 M	-20.4 M	-72.5 M	-30.6 M	-31.2 M	-	-	-	56.3 M	-	-	-	25.6 M	-	-	-	33.5 M	-	-	-	16.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in ILS currency